brought to you by 🗓 CORE



ORIGINAL ARTICLE



http://dx.doi.org/10.1016/j.phrp.2016.01.003

eISSN 2233-6052

pISSN 2210-9099

KOREA CENTERS FOR DISEASE CONTROL & PREVENTION

provided by eprints Iran University of

# Rapid Detection of Rifampicin- and Isoniazid-Resistant *Mycobacterium tuberculosis* using TaqMan Allelic Discrimination

Davood Darban-Sarokhalil<sup>a</sup>, Mohammad J. Nasiri<sup>b</sup>, Abbas A.I. Fooladi<sup>c</sup>, Parvin Heidarieh<sup>d</sup>, Mohammad M. Feizabadi<sup>e,\*</sup>

<sup>a</sup>Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. <sup>b</sup>Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

<sup>c</sup>Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. <sup>d</sup>Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran. <sup>e</sup>Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Received: November 24, 2015 Revised: December 27, 2015 Accepted: January 6, 2016

#### **KEYWORDS:**

minor groove binder (MGB), multidrug-resistant tuberculosis (MDR-TB), *Mycobacterium tuberculosis*, rapid detection, TaqMan allelic discrimination

#### Abstract

**Objectives:** Multidrug-resistant tuberculosis (MDR-TB) is a global problem that many countries are challenged with. Rapid and accurate detection of MDR-TB is critical for appropriate treatment and controlling of TB. The aim of the present study was to evaluate the TaqMan allelic discrimination without minor groove binder (MGB) as a rapid, efficient, and low-cost method for detection of drug resistant strains of *Mycobacterium tuberculosis*.

**Methods:** A total of 112 *M. tuberculosis* isolates from cases with diagnosed TB were subjected to drug susceptibility testing (DST), using the proportion method. Resistant isolates were tested for characterization of mutations in the *rpoB* and *KatG* genes by TaqMan genotyping.

**Results:** Of 112 *M. tuberculosis* isolates for which DST was performed, three, one, and two isolates were MDR, rifampin (RIF) resistant, and isoniazid (INH) resistant, respectively. According to the threshold cycle (Ct) and curve pattern of mutants, TaqMan probes detect all of the mutations in the analyzed genes (*katG* 315, AGC $\rightarrow$ ACC, *rpoB* 531, TCG $\rightarrow$ TTG, and *rpoB* 531, TCG $\rightarrow$ TGG).

**Conclusion:** The present study suggests that drug-resistant strains of *M. tuber-culosis* can be detected by pattern's curve or Ct with TaqMan probes without MGB in real-time polymerase chain reaction (PCR).

## 1. Introduction

Multidrug-resistant tuberculosis (MDR-TB) is a global problem that many countries are challenged with. MDR-TB is caused by strains of *Mycobacterium tuberculosis*  resistant to at least isoniazid (INH) and rifampin (RIF), the main first-line anti-TB drugs [1]. Rapid and accurate detection of MDR isolates is critical for appropriate treatment and controlling of TB [2–4]. The culture method is still the "gold standard" among other drug susceptibility

\*Corresponding author.

E-mail: mfeizabadi@tums.ac.ir (M.M. Feizabadi).

Copyright © 2016 Korea Centers for Disease Control and Prevention. Published by Elsevier Korea LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

testing methods of *M. tuberculosis* isolates. However, this method is time consuming and takes several weeks to be completed. In recent years, several molecular methods have been developed for detection of mutations in *rpoB* and *katG* genes that cause resistance to INH and RIF [5–7]. Of these methods, Cepheid Xpert MTB/RIF kit and the line probe assays have been commercialized [8,9]. They give users the opportunity to detect the resistant mutants rapidly, but at very high cost. Therefore, it is not possible, particularly in developing countries, to apply these methods extensively. Thus, researches have been concentrated to introduce the in-house methods to reduce the cost.

TaqMan allelic discrimination is a new technique for detection of mutations. In this method, mutations even single nucleotide polymorphisms (SNP) are detected using TaqMan probe with Minor Groove Binder (MGB) and AmpliTaq Gold DNA polymerase. The efficiency of probe hybridization reduces whenever there are mismatches between a probe and allele. Moreover, AmpliTaq Gold DNA polymerase is more likely to displace the mismatched probe rather than cleave it to release reporter dye. Recently, Wada et al [10] used TaqMan minor groove binder (MGB) probes for detection of mutations in *rpoB*, *katG*, and *embB* genes of *M. tuberculosis*.

In this study, we designed the primers and probes for 81-bp hot spot of the rpoB gene and codon 315 of katG gene. Unlike most researches that used the TaqMan allelic discrimination, we did not use the MGB for designing of probes.

Our main purpose was to evaluate TaqMan allelic discrimination without minor groove binder (MGB) for rapid detection of drug-resistant strains of *M. tuberculosis*.

## 2. Materials and methods

## 2.1. Setting

This study was performed at the Tehran University of Medical Sciences. A total of 112 isolates of *M. tuber-culosis* cultured from TB patients were included in this survey.

## 2.2. Drug susceptibility testing (DST)

Drug resistant isolates were identified among 112 isolates using proportion method on Lowenstein–Jensen (LJ) media [11].

## 2.3. DNA extraction

DNA was extracted from the bacterial colonies according to the method of van Soolingen et al [12]. A commercial DNA extraction kit (Invitek, Germany) was used for extraction of DNA from clinical specimens. The optical density of extracted DNA from standard strain and clinical specimens was determined at 260 nm using NanoDrop 1000 (Thermo Scientific, USA).

#### 2.4. TaqMan analysis

TaqMan probes and primers for detection of mutations in *rpoB* and *katG* genes were designed using the Primer Express program (Applied Biosystems, Foster City, CA, USA) and were synthesized by Metabion (Martinsried, Germany). The primers and probes of *rpoB* gene were F: 5'-TCACACCGCAGACGTTGATC-3', R: 5'-CGTAGTGCGACGGGTGC-3', P1: 5'-FAM-CAGCT-GAGCCAATTCATGGACCAGA-BHQ-1-3' (Tm = 67.2), and P2: 5'-VIC-CACAAGCGCCGACTGTCGGC-BHQ-1-3' (Tm = 68.1). The primers and probe of *katG* gene were F: 5'-GGGCTTGGGCTGGAAGA-3', R: 5'-GGAAACTGTTGTCCCATTCG-3', and P: 5'-FAM-ACGCGATCACCAGCGGCA-BHQ-1-3' (Tm = 65.0).

The PCR reaction mixture was  $1 \times \text{reaction buffer}$  [50 mM KCl, 10 mM Tris-HCl (pH 9.0), 2 mM MgCl<sub>2</sub>], 2.5 mM of dNTPs, 2 U *Taq* DNA-polymerase (miTaq, Metabion, Martinsried, Germany), and 20 pmol each of primers in total volume of 50 µL. Amplification was performed in a Mastercycler Gradient (Eppendorf, Germany) using the following program: initial denaturation at 95°C for 10 minutes and 35 cycles of denaturation at 94°C for 25 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 30 seconds, and the final extension at 72°C for 5 minutes. After amplification, PCR products were sequenced.

The mixture of real-time PCR reaction was done using TaqMan Genotyping Master Mix (Applied Biosystems) and the mentioned primers and probes. The real-time PCR apparatus (Bioer, Hangzhou, and P.R., China) was programmed as follows: initial denaturation at 94°C for 10 minutes followed by 40 cycles of 94°C for 25 seconds, 60°C for 55 seconds. To obtain reproducibility of reaction, the amplification was run in triplicate on DNA obtained from H37Rv strain, mycobacterial isolates, and clinical samples. All samples were run with the DNA obtained from H37Rv strain. Human white blood cell DNA and beta actin gene were used as external and internal controls, respectively [13]. Diluted DNA of H37Rv was used for the evaluation of the sensitivity. Specificity of the reaction was evaluated on DNA from other mycobacteria and potentially pathogenic bacteria in the respiratory tract and human cells that was used in the previous study [14].

# 3. Results

Of 112 isolates, three, one, and two were MDR, RIF resistant and INH resistant, respectively. The results of sequencing of *rpo*B and *kat*G genes are shown in Table 1. Fig. 1 shows the analysis of DNA from mycobacteria with TaqMan probes. As described above, AmpliTaq Gold DNA polymerase could detect the mismatches between a probe and allele even SNP. According the figure, the pattern curve of H37Rv strain is different from the mutants. Moreover, the luminescence intensity

Phenotypic characteristic of resistant isolates	Genotypic characteristic of resistant isolates
Resistant to INH	<i>katG</i> 315, AGC $\rightarrow$ ACC
Resistant to RIF	<i>rpoB</i> 531, TCG $\rightarrow$ TTG
	<i>rpoB</i> 531, TCG→TGG

 Table 1.
 Results of sequencing of 81-bp hot spot of the rpoB gene and codon 315 of the katG gene.

INH = isoniazid; RIF = rifampin.

or threshold cycle (Ct) was higher when mutations were present in the genes. The difference of curve patterns can differentiate the susceptible and resistance isolates. Therefore real-time PCR detected the all of the mutations in *rpoB* and *katG* genes.

With the exception of *M. tuberculosis* complex (*M. bovis, M. bovis, BCG, M. africanum*, and *M. microti*), no luminescence was found. The results of PCR in serial dilutions demonstrated high efficiency of the technique as it detected 10 pg of *M. tuberculosis* DNA.

# 4. Discussion

Real-time PCR system in combination with MGB probes has been applied to analyze single-nucleotide

polymorphisms [10,15]. The MGB probes have been used in other studies for detection and distinction of onebase mismatches due to their high specificity and sensitivity [16], so it can be a powerful tool for control of drug-resistant *M. tuberculosis*. In this study, we developed a rapid, efficient, and low-cost real-time PCR-based system without MGB probes for detection of the mutations associated with INH and RIF resistance in *M. tuberculosis*.

Despite our probes detecting all mutations in the mentioned regions of the katG and rpoB genes as little as 3 hours from the preparation of DNAs from clinical samples, our method had limitation in use because it could not identify MDR and XDR strains that genetically belonged to the Harrlem3 and Harrlem4 clusters in spoligotyping. Interestingly, there were no mutations in the 81-bp hot spot of the rpoB gene and codon 315 of *katG* gene of these strains as determined by DNA sequencing (data not shown). Therefore, the result of this study gives evidence that a single molecular method for detection of drug-resistant M. tuberculosis is not sufficient. In comparison with the conventional and commercial methods (i.e., line probes or Cepheid Xpert MTB/RIF kit) for detection of MDR-TB, our in-house technique was less time- and fund-consuming, with costs five times cheaper than commercial kits.



Figure 1. The curve patterns of H37Rv strain, negative control and *Mycobacterium tuberculosis* mutants with and without *katG* 315, AGC $\rightarrow$ ACC mutation.

Many studies used real-time PCR for detection of mutations in *rpoB* and *katG* genes [17–21] but, to our knowledge, this study is the first one that uses the TaqMan allelic discrimination without MGB. Our study suggests that drug-resistant *M. tuberculosis* can be detected by pattern's curve or Ct with TaqMan probes without MGB in real-time PCR. We evaluated our probes on limited resistant *M. tuberculosis* isolates (*katG* 315, AGC  $\rightarrow$  ACC, *rpoB* 531, TCG  $\rightarrow$  TTG and *rpoB* 531, TCG  $\rightarrow$  TGG), and the mentioned mutations are the common mutations that cause RIF- and INH-resistant strains. However, for more confirmation, evaluation of other mutations in the 81-bp hot spot of the *rpoB* gene as well as more drug-resistant strains is needed.

## **Conflicts of interest**

All authors have no conflicts of interest to declare.

#### Acknowledgments

This work is a part of project 9627 supported by Tehran University of Medical Sciences.

## References

- Nasiri MJ, Dabiri H, Darban-Sarokhalil D, et al. Prevalence of drug-resistant tuberculosis in Iran: systematic review and metaanalysis. Am J Infect Control 2014 Sep;42(11):1212–8.
- Adékambi T, Colson P, Drancourt M. rpoB-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. J Clin Microbiol 2003 Dec;41(12):5699–708.
- Palomino JC. Molecular detection, identification, and drug resistance detection in *Mycobacterium tuberculosis*. FEMS Immunol Med Microbiol 2009 Jul;56(2):103–11.
- 4. Catanzaro A, Rodwell TC, Catanzaro DG, et al. Performance comparison of three rapid tests for the diagnosis of drug-resistant tuberculosis. PLoS One 2015 Aug 31;10(8):e0136861.
- Marín M, De Viedma DG, Ruíz-Serrano MJ, et al. Rapid direct detection of multiple rifampin and isoniazid resistance mutations in *Mycobacterium tuberculosis* in respiratory samples by realtime PCR. Antimicrob Agents Chemother 2004 Nov;48(11): 4293–300.
- 6. Sali M, De Maio F, Caccuri F, et al. Multicenter evaluation of the Anyplex Plus MTB/NTM MDR-TB assay for rapid detection of *Mycobacterium tuberculosis* complex and multidrug-resistant isolates in pulmonary and extrapulmonary specimens. J Clin Microbiol; 2015 Oct. pii: JCM.01904-15.

- Mani V, Wang S, Inci F, et al. Emerging technologies for monitoring drug-resistant tuberculosis at the point-of-care. Adv Drug Deliv Rev 2014 Nov;78:105–17.
- Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010 Sep;363(11):1005–15.
- 9. World Health Organization (WHO). Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement 2008.
- Wada T, Maeda S, Tamaru A, et al. Dual-probe assay for rapid detection of drug-resistant *Mycobacterium tuberculosis* by realtime PCR. J Clin Microbiol 2004 Nov;42(11):5277–85.
- Nasiri MJ, Rezaei F, Zamani S, et al. Drug resistance pattern of Mycobacterium tuberculosis isolates from patients of five provinces of Iran. Asian Pac J Trop Med 2014 Mar;7(3):193-6.
- van Soolingen D, De Haas PE, Hermans PW, et al. DNA fingerprinting of *Mycobacterium tuberculosis*. Methods Enzymol 1994; 235:196–205.
- Mehndiratta M, Palanichamy JK, Ramalingam P, et al. Fluorescence acquisition during hybridization phase in quantitative realtime PCR improves specificity and signal-to-noise ratio. Biotechniques 2008 Dec;45(6):625-6.
- 14. Darban-Sarokhalil D, Fooladi A, Bameri Z, et al. Cytochrome CYP141: a new target for direct detection of *Mycobacterium tuberculosis* from clinical specimens. Acta Microbiol Immunol Hung 2011 Sep;58(3):211–7.
- 15. van Doorn HR, Claas EC, Templeton KE, et al. Detection of a point mutation associated with high-level isoniazid resistance in *Mycobacterium tuberculosis* by using real-time PCR technology with 3'-minor groove binder-DNA probes. J Clin Microbiol 2003 Oct;41(10):4630-5.
- Kutyavin IV, Afonina IA, Mills A, et al. 3'-Minor groove binder-DNA probes increase sequence specificity at PCR extension temperatures. Nucleic Acids Res 2000 Jan 15;28(2):655–61.
- 17. de Viedma DG, Infantes MdSD, Lasala F, et al. New real-time PCR able to detect in a single tube multiple rifampin resistance mutations and high-level isoniazid resistance mutations in *Mycobacterium tuberculosis*. J Clin Microbiol 2002 Mar;40(3): 988–95.
- Ramirez MV, Cowart KC, Campbell PJ, et al. Rapid detection of multidrug-resistant *Mycobacterium tuberculosis* by use of realtime PCR and high-resolution melt analysis. J Clin Microbiol 2010 Nov;48(11):4003–9.
- Haeili M, Fooladi A, Bostanabad S, et al. Rapid screening of rpoB and katG mutations in *Mycobacterium tuberculosis* isolates by high-resolution melting curve analysis. Indian J Med Microbiol 2014 Oct–Dec;32(4):398–403.
- 20. Choi GE, Lee SM, Yi J, et al. High-resolution melting curve analysis for rapid detection of rifampin and isoniazid resistance in *Mycobacterium tuberculosis* clinical isolates. J Clin Microbiol 2010 Nov;48(11):3893–8.
- Park S-H, Kim C-K, Jeong H-R, et al. Evaluation and comparison of molecular and conventional diagnostic tests for detecting tuberculosis in Korea, 2013. Osong Public Health Res Perspect 2014 Dec;5(Suppl.):S3-7.